COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00332917




Registration number
NCT00332917
Ethics application status
Date submitted
1/06/2006
Date registered
2/06/2006
Date last updated
26/01/2009

Titles & IDs
Public title
An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients
Scientific title
An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients
Secondary ID [1] 0 0
2006-000858-45
Secondary ID [2] 0 0
S308.3.006
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Early Stage Parkinson's Disease 0 0
Condition category
Condition code
Neurological 0 0 0 0
Parkinson's disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Pardoprunox

Experimental: 1 -


Treatment: Drugs: Pardoprunox
12-42 mg

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety: laboratory data, adverse events, vital signs, ECG
Timepoint [1] 0 0
24 weeks
Secondary outcome [1] 0 0
UPDRS parts 1, 2 and 3, CGI-severity, CGI-improvement, PDQ-39 total score: all change from baseline
Timepoint [1] 0 0
24 weeks

Eligibility
Key inclusion criteria
- Patients who have completed S308.3.001 trial
Minimum age
30 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patients with medically relevant abnormal findings (ECG, physical examination, AEs) at
end of the maintenance phase (visit M6, week 24) of study S308.3.001

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Kansas
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Missouri
Country [9] 0 0
United States of America
State/province [9] 0 0
Nevada
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
North Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
Rhode Island
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
United States of America
State/province [16] 0 0
Vermont
Country [17] 0 0
Argentina
State/province [17] 0 0
Buenos Aires
Country [18] 0 0
Argentina
State/province [18] 0 0
Capital Federal, CBA
Country [19] 0 0
Argentina
State/province [19] 0 0
Ciudad Autonoma de Buenos Aires
Country [20] 0 0
Argentina
State/province [20] 0 0
Ciudad de Buenos Aires
Country [21] 0 0
Argentina
State/province [21] 0 0
Cordoba
Country [22] 0 0
Belgium
State/province [22] 0 0
Brussels
Country [23] 0 0
Belgium
State/province [23] 0 0
Genk
Country [24] 0 0
Belgium
State/province [24] 0 0
Wilrijk
Country [25] 0 0
Bulgaria
State/province [25] 0 0
Plovdiv
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Sofia
Country [27] 0 0
Canada
State/province [27] 0 0
Barrie
Country [28] 0 0
Canada
State/province [28] 0 0
Calgary
Country [29] 0 0
Canada
State/province [29] 0 0
Greenfield Park
Country [30] 0 0
Canada
State/province [30] 0 0
Markham
Country [31] 0 0
Canada
State/province [31] 0 0
Ottawa
Country [32] 0 0
Canada
State/province [32] 0 0
Quebec
Country [33] 0 0
Canada
State/province [33] 0 0
Saskatoon
Country [34] 0 0
Canada
State/province [34] 0 0
Toronto
Country [35] 0 0
Chile
State/province [35] 0 0
Providencia
Country [36] 0 0
Chile
State/province [36] 0 0
San Miguel
Country [37] 0 0
Chile
State/province [37] 0 0
Santiago de Chile
Country [38] 0 0
Chile
State/province [38] 0 0
Valdivia
Country [39] 0 0
Colombia
State/province [39] 0 0
Bogota
Country [40] 0 0
Colombia
State/province [40] 0 0
Cali
Country [41] 0 0
Colombia
State/province [41] 0 0
Medellin
Country [42] 0 0
Croatia
State/province [42] 0 0
Rijeka
Country [43] 0 0
Croatia
State/province [43] 0 0
Split
Country [44] 0 0
Croatia
State/province [44] 0 0
Zagreb
Country [45] 0 0
Finland
State/province [45] 0 0
Kuopio
Country [46] 0 0
Finland
State/province [46] 0 0
Lappeenranta
Country [47] 0 0
Finland
State/province [47] 0 0
Oulun yliopisto
Country [48] 0 0
Finland
State/province [48] 0 0
Tampere
Country [49] 0 0
Finland
State/province [49] 0 0
Turku
Country [50] 0 0
India
State/province [50] 0 0
Bangalore
Country [51] 0 0
India
State/province [51] 0 0
Hyderabaad
Country [52] 0 0
India
State/province [52] 0 0
Mumbai
Country [53] 0 0
India
State/province [53] 0 0
New Delhi
Country [54] 0 0
India
State/province [54] 0 0
Thiruvananthapuram
Country [55] 0 0
India
State/province [55] 0 0
Visakhapatnam
Country [56] 0 0
Israel
State/province [56] 0 0
Haifa
Country [57] 0 0
Israel
State/province [57] 0 0
Petach-Tikva
Country [58] 0 0
Israel
State/province [58] 0 0
Ramat-Gan
Country [59] 0 0
Israel
State/province [59] 0 0
Tel Aviv
Country [60] 0 0
Mexico
State/province [60] 0 0
Aguascalientes
Country [61] 0 0
Mexico
State/province [61] 0 0
Guadalajara - Jalisco
Country [62] 0 0
Mexico
State/province [62] 0 0
Monterrey N.L.
Country [63] 0 0
Mexico
State/province [63] 0 0
Tlalpan
Country [64] 0 0
New Zealand
State/province [64] 0 0
Christchurch
Country [65] 0 0
New Zealand
State/province [65] 0 0
Wellington South
Country [66] 0 0
Peru
State/province [66] 0 0
Barrios Altos-Lima
Country [67] 0 0
Peru
State/province [67] 0 0
La Victoria-Lima
Country [68] 0 0
Peru
State/province [68] 0 0
Lima
Country [69] 0 0
Peru
State/province [69] 0 0
San Isidro-Lima
Country [70] 0 0
Peru
State/province [70] 0 0
Surco-Lima
Country [71] 0 0
Romania
State/province [71] 0 0
Brasov
Country [72] 0 0
Romania
State/province [72] 0 0
Bucuresti
Country [73] 0 0
Romania
State/province [73] 0 0
Craiova
Country [74] 0 0
Romania
State/province [74] 0 0
Mures
Country [75] 0 0
Russian Federation
State/province [75] 0 0
Kazan
Country [76] 0 0
Russian Federation
State/province [76] 0 0
Moscow
Country [77] 0 0
Russian Federation
State/province [77] 0 0
Smolensk
Country [78] 0 0
Russian Federation
State/province [78] 0 0
St Petersburg
Country [79] 0 0
Russian Federation
State/province [79] 0 0
St. Petersburg
Country [80] 0 0
Russian Federation
State/province [80] 0 0
Yaroslav
Country [81] 0 0
Serbia
State/province [81] 0 0
Belgrade
Country [82] 0 0
Serbia
State/province [82] 0 0
Nis
Country [83] 0 0
Slovakia
State/province [83] 0 0
Bratislava
Country [84] 0 0
Slovakia
State/province [84] 0 0
Levice
Country [85] 0 0
Slovakia
State/province [85] 0 0
Nitra
Country [86] 0 0
Slovakia
State/province [86] 0 0
Zilina
Country [87] 0 0
South Africa
State/province [87] 0 0
Cape Town
Country [88] 0 0
South Africa
State/province [88] 0 0
Durban
Country [89] 0 0
South Africa
State/province [89] 0 0
Gauteng
Country [90] 0 0
South Africa
State/province [90] 0 0
Pretoria
Country [91] 0 0
Sweden
State/province [91] 0 0
Goteborg
Country [92] 0 0
Sweden
State/province [92] 0 0
Norrkoping
Country [93] 0 0
Sweden
State/province [93] 0 0
Stockholm
Country [94] 0 0
Ukraine
State/province [94] 0 0
Kharkiv
Country [95] 0 0
Ukraine
State/province [95] 0 0
Kyiv
Country [96] 0 0
Ukraine
State/province [96] 0 0
Lviv
Country [97] 0 0
Ukraine
State/province [97] 0 0
Vinnitsa

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Solvay Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a multicenter, 6 months open label safety extension study for all patients who are
willing and eligible to continue from the pivotal, double-blind S308.3.001 trial
Trial website
https://clinicaltrials.gov/show/NCT00332917
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Global Clinical Director Solvay
Address 0 0
Solvay Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications